Previous 10 | Next 10 |
STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland , Chief Execu...
STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome sequencing as a first-tier test, to be prioritized over multi-gene panels for all individuals wit...
-- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases -- -- Sema4|GeneDx contributes to latest data in the SeqFirst study being presented at the American Society of Human Genetics Annual Meeting -- STAMFORD, Conn., Oc...
STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels. The study demonstrates that using ...
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child Neurology Society (CNS) Annual Meeting on October 13, 2022 STAMFORD, Conn., ...
STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboration among premier non-profit, academ...
New York, New York--(Newsfile Corp. - September 15, 2022) - Levi & Korsinsky, LLP notifies investors in Sema4 Holdings, Corp. ("Sema4 Holdings Corp." or the "Company") (NASDAQ: SMFR) of a class action securities lawsuit. The lawsuit on behalf of Sema4 Holdings Corp. investors has been c...
New York, New York--(Newsfile Corp. - September 14, 2022) - Levi & Korsinsky, LLP notifies investors in Sema4 Holdings, Corp. ("Sema4 Holdings Corp." or the "Company") (NASDAQ: SMFR) of a class action securities lawsuit. The lawsuit on behalf of Sema4 Holdings Corp. investors has been c...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - September 9, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, ...
NEW YORK, NY / ACCESSWIRE / September 7, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7, 2022 deadline to seek the role of...
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Company Name:
SMFR Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...